Exchange Traded Concepts LLC Increases Holdings in Zoetis Inc. $ZTS

Exchange Traded Concepts LLC increased its stake in Zoetis Inc. (NYSE:ZTS) by 55.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 11,994 shares of the company’s stock after buying an additional 4,266 shares during the period. Exchange Traded Concepts LLC’s holdings in Zoetis were worth $1,509,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. increased its holdings in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after buying an additional 419,777 shares during the last quarter. Nordea Investment Management AB boosted its stake in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Brown Advisory Inc. grew its position in shares of Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after acquiring an additional 250,829 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the period. Finally, Alliancebernstein L.P. increased its stake in shares of Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after purchasing an additional 496,320 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $117.45 on Thursday. The firm has a market cap of $49.58 billion, a P/E ratio of 19.51, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company’s 50 day moving average is $122.97 and its 200-day moving average is $128.49. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the firm earned $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Piper Sandler reissued a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. William Blair restated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.